Top

Published in:

01-08-2017 | Original Article

Randomized, double-blind, placebo-controlled trial to compare solifenacin versus trospium chloride in the relief of double-J stent-related symptoms

Authors: Mohamed H. Abdelhamid, Ahmed S. Zayed, Waleed E. Ghoneima, Akrm A. Elmarakbi, Mohamed S. El Sheemy, Ahmed Aref, Ahmed Abdelbary, Hani H. Nour

Published in: World Journal of Urology | Issue 8/2017

Abstract

Purpose

We aimed to compare the safety and efficacy of solifenacin versus trospium chloride and compare each drug versus placebo regarding the relief of stent-related symptoms following uncomplicated ureteroscopic lithotripsy (URSL).

Methods

In a prospective, randomized, double-blind study, 210 eligible patients who underwent URSL with double-J stent insertion were recruited and randomly assigned to either the first group, receiving solifenacin (10 mg), second group, receiving trospium chloride (60 mg), or the third group, receiving placebo (one tablet). All patients were kept on study medication once daily during the entire 2-week postoperative period. All subjects were asked to complete a brief-form questionnaire to assess the lower urinary symptoms, stent-related body pain and hematuria, preoperatively and 2 weeks postoperatively.

Results

There were no statistically significant differences among the study groups in terms of mean age, gender, anthropometric measurements, stone and stent criteria. The overall symptom score, urgency, urge incontinence, flank pain, urethral pain and gross hematuria scores were significantly lower in solifenacin group compared to trospium chloride and placebo groups (p < 0.001). Concerning frequency and nocturia, there was no significant difference in mean scores across all groups. Drug-related side effects, particularly constipation, were higher in trospium group than in solifenacin one.

Conclusions

Solifenacin treatment showed significant improvement in almost all domains of stent-related symptoms than trospium. In terms of safety and tolerance, both drugs were comparable. Future studies should be designed to address the impact of combined drugs and lower doses in the management of DJ stent-related symptoms.

Makarov DV, Trock BJ, Allaf ME, Matlaga BR (2008) The effect of ureteral stent placement on post-ureteroscopy complications: a meta-analysis. Urology 71:79680CrossRef

Gunlusoy B, Degirmenci T, Arslan M, Kozacýoglu Z, Minareci S, Ayder AR (2008) Is ureteral catheterization necessary after ureteroscopic lithotripsy for uncomplicated upper ureteral stones? J Endourol 22:1645–1648CrossRefPubMed

Chen YT, Chen J, Wong WY, Shei-Dei Yang ST, Hsieh CH, Wang CC (2002) Is ureteral stenting necessary after uncomplicated ureteroscopic lithotripsy? A prospective, randomized controlled trial. J Urol 167:1977–1980CrossRefPubMed

Thomas R (1993) Indwelling ureteral stents: impact of material and shape on patient comfort. J Endourol 7:137–140CrossRefPubMed

Joshi HB, Stainthorpe A, MacDonagh RP, Keeley FX, Timoney AG (2003) Indwelling ureteral stents: evaluation of symptoms, quality of life and utility. J Urol 169(3):1065–1069CrossRefPubMed

Al-Ba’adani T, Ghilan A, El-Nono I, Alwan M, Bingadhi A (2006) Whether post-ureteroscopy stenting is necessary or not? Saudi Med J 27:845–848PubMed

Sighinolfi MC, Micali S, De Stefani S, Mofferdin A, Grande A, Giacometti M, Ferrari N, Rivalta M, Bianchi G (2007) Indwelling ureteral stents and sexual health: a prospective, multivariate analysis. J Urol 178:229–231CrossRefPubMed

Damiano R, Autorino R, De Sio M, Cantiello F, Quarto G, Perdonà S, Sacco R, D’Armiento M (2005) Does the size of ureteral stent impact urinary symptoms and quality of life? A prospective randomized study. Eur Urol 48:673–678CrossRefPubMed

Park SC, Jung SW, Lee JW, Rim JS (2009) The effects of tolterodine extended release and Alfuzosin for the treatment of double-J stent-related symptoms. J Endourol 23:1913–1917CrossRefPubMed

10.

Deliveliotis C, Chrisofos M, Gougousis E, Papatsoris A, Dellis A, Varkarakis IM (2006) Is there a role for alpha1-blockers in treating double-J stent-related symptoms? Urology 67:35–39CrossRefPubMed

11.

Gupta M, Patel T, Xavier K, Maruffo F, Lehman D, Walsh R, Landman J (2010) Prospective randomized evaluation of periureteral botulinum toxin type A injection for ureteral stent pain reduction. J Urol 183:598–602CrossRefPubMed

12.

Vardy MD, Mitcheson HD, Samuels TA, Wegenke JD, Forero-Schwanhaeuser S, Marshall TS, He W (2009) Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT—a double-blind, placebo-controlled trial. Int J Clin Pract 63(12):1702–1714CrossRefPubMed

13.

Ho CH, Chang TC, Lin HH, Liu SP, Huang KH, Yu HJ (2010) Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms. J Formos Med Assoc 109(10):702–708CrossRefPubMed

14.

Lee YJ, Huang KH, Yang HJ, Chang HC, Chen J, Yang TK (2013) Solifenacin improves double-J stent-related symptoms in both genders following uncomplicated ureteroscopic lithotripsy. Urolithiasis 41:247–252CrossRefPubMed

15.

Kuyumcuoglu U, Eryildirim B, Tuncer M, Faydaci G, Tarhan F, Ozgül A (2012) Effectiveness of medical treatment in overcoming the ureteral double-J stent related symptoms. Can Urol Assoc J 6(6):234–237CrossRef

16.

Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J, STAR study group (2005) A comparison for the efficacy and tolerability of solifenacin succinate and extended release of tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 48(3):464–470CrossRefPubMed

17.

Herschorn S, Stothers L, Carlson K, Egerdie B, Gajewski JB, Pommerville P, Schulz J, Radomski S, Drutz H, Barkin J, Paradiso-Hardy F (2010) Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily results of VECTOR trial. J Urol 183:1892–1898CrossRefPubMed

18.

Burger M, Betz D, Hampel C, Vogel M (2014) Efficacy and tolerability of solifenacin in men with overactive bladder: results of an observational study. World J Urol 32:1041–1047CrossRefPubMed

19.

Basra R, Kellher C (2008) A review of solifenacin in the treatment of urinary incontinence. Ther Clin Risk Manag 4(1):117–128PubMedPubMedCentral

20.

Kosilov KV, Loparev SA, Ivanovskaya MA, Kosilova LV (2014) Comparative effectiveness of combined low- and standard-dose trospium and solifenacin for moderate overactive bladder symptoms in elderly men and women. Urol Int 93(4):470–473CrossRefPubMed

21.

Oefelein MG, Tong W, Kerr S, Bhasi K, Patel RK, Yu D (2013) Effect of concomitant administration of trospium chloride extended release on the steady-state pharmacokinetics of metformin in healthy adults. Clin Drug Investig 33:123–131CrossRefPubMedPubMedCentral

22.

Marquis J, Schneider MP, Spencer B, Bugnon O, Du Pasquier S (2014) Exploring the implementation of a medication adherence programme by community pharmacists: a qualitative study. Int J Clin Pharm 36(5):1014–1022CrossRefPubMed

23.

World Medical Association (2001) World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bull World Health Organ 79(4):373PubMedCentral

24.

Rane A, Saleemi A, Cahill D, Sriprasad S, Shrotri N, Tiptaft R (2001) Have stent-related symptoms anything to do with placement technique? J Endourol 15(7):741–745CrossRefPubMed

25.

Al-Kandari AM, Al-Shaiji TF, Shaaban H, Ibrahim HM, Elshebiny YH, Shokeir AA (2007) Effects of proximal and distal ends of double-J ureteral stent position on postprocedural symptoms and quality of life: a randomized clinical trial. J Endourol 21:698–702CrossRefPubMed

26.

Ertuk E, Sessions A, Joseph V (2003) Impact of ureteral stent diameter on symptoms and tolerability. J Endourol 17(2):59–62CrossRef

27.

Agarwal A, Dhiraaj S, Singhal V, Kapoor R, Tandon M (2006) Comparison of efficacy of oxybutynin and tolterodine for prevention of catheter-related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study. Br J Anaesth 96:377–380CrossRefPubMed

28.

Lim KT, Kim YT, Lee TY, Park SY (2011) Effects of tamsulosin, solifenacin and combination therapy for the treatment of ureteral stent related discomforts. Korean J Urol 52:485–488CrossRefPubMedPubMedCentral

29.

Ito Y, Kashiwabara M, Yoshida A, Hikiyama E, Onoue S, Yamada S (2016) Muscarinic receptor binding in rat bladder urothelium and detrusor muscle by intravesical solifenacin. Biol Pharm Bull 39(7):1167–1171CrossRefPubMed

Title: Randomized, double-blind, placebo-controlled trial to compare solifenacin versus trospium chloride in the relief of double-J stent-related symptoms
Authors: Mohamed H. Abdelhamid
Ahmed S. Zayed
Waleed E. Ghoneima
Akrm A. Elmarakbi
Mohamed S. El Sheemy
Ahmed Aref
Ahmed Abdelbary
Hani H. Nour
Publication date: 01-08-2017
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 8/2017
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-016-1988-y

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Randomized, double-blind, placebo-controlled trial to compare solifenacin versus trospium chloride in the relief of double-J stent-related symptoms

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2017

Platinum-refractory germ cell tumors: an update on current treatment options and developments

Residual tumor resection (RTR)

A double-blind, placebo-controlled randomized clinical trial to evaluate the efficacy of tranexamic acid in irrigant solution on blood loss during percutaneous nephrolithotomy: a pilot study from tertiary care center of North India

Perioperative patient education improves long-term satisfaction rates of low-risk prostate cancer patients after radical prostatectomy

Testis cancer: some problems still remain unsolved

Improved decision making in intermediate-risk prostate cancer: a multicenter study on pathologic and oncologic outcomes after radical prostatectomy